Back to top
more

Enzo Biochem (ENZ)

(Delayed Data from NYSE)

$1.09 USD

1.09
120,187

0.00 (0.00%)

Updated Apr 22, 2024 04:00 PM ET

After-Market: $1.10 +0.01 (0.92%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern

by Zacks Equity Research

Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.

    Pacira Pharmaceuticals Focuses on Exparel's Label Expansion

    by Zacks Equity Research

    Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.

      Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag

      by Zacks Equity Research

      Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.

        Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss

        by Zacks Equity Research

        Novo Nordisk A/S (NVO) beat earnings estimates but missed revenue estimates in Q2. Robust performance for Victoza and Tresiba will drive growth.

          Intrexon (XON) Q2 Loss Narrower than Expected, Revenues Miss

          by Zacks Equity Research

          Intrexon Corporation (XON) incurred narrower than expected loss and missed revenue estimates in Q2.

            Catalyst (CPRX) Posts Narrower than Expected Loss in Q2

            by Zacks Equity Research

            Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.

              Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised

              by Zacks Equity Research

              Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.

                The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss

                by Zacks Equity Research

                The Medicines Company (MDCO) reports wider-than-expected loss with revenues missing estimates. The top line also decreases year over year due to low Angiomax sales.

                  BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls

                  by Zacks Equity Research

                  BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.

                    Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls

                    by Zacks Equity Research

                    Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

                      Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact

                      by Zacks Equity Research

                      Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.

                        Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress

                        by Zacks Equity Research

                        Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.

                          Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y

                          by Zacks Equity Research

                          Agios (AGIO) reports wider-than-expected loss with revenues marginally lagging estimates. However, the top line improves year over year, thanks to reimbursement received from Celgene.

                            Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss

                            by Zacks Equity Research

                            Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.

                              Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update

                              by Zacks Equity Research

                              Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.

                                PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y

                                by Zacks Equity Research

                                PDL BioPharma's (PDLI) earnings surpass expectations. Revenues also significantly increase year over year, thanks to a rise in fair value of the Depomed royalty asset.

                                  Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2

                                  by Zacks Equity Research

                                  Epizyme, Inc. (EPZM) posted narrower-than-expected loss in Q2 as the company focuses on the development of tazemetostat.

                                    Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass

                                    by Zacks Equity Research

                                    Juno Therapeutics (JUNO) reports wider-than-expected loss but revenues beat estimates. However, revenue decreased year-over-year.

                                      Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag

                                      by Zacks Equity Research

                                      Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.

                                        AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2

                                        by Zacks Equity Research

                                        AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.

                                          Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates

                                          by Zacks Equity Research

                                          Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.

                                            Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss

                                            by Zacks Equity Research

                                            Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.

                                              Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised

                                              by Zacks Equity Research

                                              Corcept Therapeutics Incorporated's (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.

                                                Strongbridge Biopharma (SBBP) Rises: Stock Moves 17% Higher

                                                by Zacks Equity Research

                                                Strongbridge Biopharma plc (SBBP) shares rose almost 17% in the last trading session.

                                                  Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise

                                                  by Zacks Equity Research

                                                  Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.